{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:08:21Z","timestamp":1791986901494,"version":"4.4.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T00:00:00Z","timestamp":1312243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1756-8722-4-32","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T18:20:16Z","timestamp":1312309216000},"source":"Crossref","is-referenced-by-count":19,"title":["Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line"],"prefix":"10.1186","volume":"4","author":[{"given":"Seiichi","family":"Okabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuzo","family":"Tauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,2]]},"reference":[{"key":"166_CR1","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005, 105: 2640-2653. 10.1182\/blood-2004-08-3097.","journal-title":"Blood"},{"key":"166_CR2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","volume":"145","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J: New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006, 145: 913-923.","journal-title":"Ann Intern Med"},{"key":"166_CR3","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006, 354: 2542-2551. 10.1056\/NEJMoa055104.","journal-title":"N Engl J Med"},{"key":"166_CR4","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, ENESTnd Investigators: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010, 362: 2251-2259. 10.1056\/NEJMoa0912614.","journal-title":"N Engl J Med"},{"key":"166_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1756-8722-3-47","volume":"3","author":"G Wei","year":"2010","unstructured":"Wei G, Rafiyath S, Liu D: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol. 2010, 3: 47-10.1186\/1756-8722-3-47.","journal-title":"J Hematol Oncol"},{"key":"166_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","volume":"109","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, Talpaz M, Cortes J: Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007, 109: 497-499. 10.1182\/blood-2006-07-035493.","journal-title":"Blood"},{"key":"166_CR7","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqu\u00e9 C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010, 362: 2260-2270. 10.1056\/NEJMoa1002315.","journal-title":"N Engl J Med"},{"key":"166_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1756-8722-4-6","volume":"4","author":"H Quentmeier","year":"2011","unstructured":"Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG: BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol. 2011, 4: 6-10.1186\/1756-8722-4-6.","journal-title":"J Hematol Oncol"},{"key":"166_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1182\/blood.V98.2.343","volume":"98","author":"B O'Laughlin-Bunner","year":"2001","unstructured":"O'Laughlin-Bunner B, Radosevic N, Taylor ML, DeBerry C, Metcalfe DD, Zhou M, Lowell C, Linnekin D: Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. Blood. 2001, 98: 343-350. 10.1182\/blood.V98.2.343.","journal-title":"Blood"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-4-32.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-8722-4-32\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-4-32.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T22:20:42Z","timestamp":1548195642000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-4-32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,2]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["166"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-4-32","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,2]]},"article-number":"32"}}